Miravo Healthcare™ Announces First Quarter 2022 Results

Blexten Canadian Prescriptions Increased 21% Year-Over-Year –
Suvexx Canadian Prescriptions Increased 120% Year-Over-Year –

Miravo to Hold Virtual Annual Meeting May 16th at 9:00 a.m. ET

Mississauga, Ontario, Canada – May 16, 2022 – Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months ended March 31, 2022.  For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements for the three months ended March 31, 2022, which are available on the Company’s website (www.miravohealthcare.com).  All figures are in Canadian dollars, unless otherwise noted.

Read full release here.